Market closed
Abcellera Biologics/$ABCL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Abcellera Biologics
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Ticker
$ABCL
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Vancouver, Canada
Employees
586
Website
ABCL Metrics
BasicAdvanced
$800M
Market cap
-
P/E ratio
-$0.61
EPS
0.35
Beta
-
Dividend rate
Price and volume
Market cap
$800M
Beta
0.35
52-week high
$6.06
52-week low
$2.34
Average daily volume
2.7M
Financial strength
Current ratio
9.336
Quick ratio
8.477
Long term debt to equity
6.147
Total debt to equity
6.623
Management effectiveness
Return on assets (TTM)
-13.26%
Return on equity (TTM)
-15.55%
Valuation
Price to revenue (TTM)
24.094
Price to book
0.74
Price to tangible book (TTM)
0.82
Price to free cash flow (TTM)
-4.013
Growth
Revenue change (TTM)
-34.59%
Earnings per share change (TTM)
35.86%
3-year revenue growth (CAGR)
-57.96%
3-year earnings per share growth (CAGR)
-1.81%
What the Analysts think about ABCL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Abcellera Biologics stock.
ABCL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ABCL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ABCL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Abcellera Biologics stock?
Abcellera Biologics (ABCL) has a market cap of $800M as of December 21, 2024.
What is the P/E ratio for Abcellera Biologics stock?
The price to earnings (P/E) ratio for Abcellera Biologics (ABCL) stock is 0 as of December 21, 2024.
Does Abcellera Biologics stock pay dividends?
No, Abcellera Biologics (ABCL) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Abcellera Biologics dividend payment date?
Abcellera Biologics (ABCL) stock does not pay dividends to its shareholders.
What is the beta indicator for Abcellera Biologics?
Abcellera Biologics (ABCL) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.